Wolfe Research analyst Doug Schenkel upgraded Guardant Health (GH) to Outperform from Peer Perform with a $75 price target The company had a “solid” analyst day and Wolfe’s sum-of-the-parts analysis yields 30% upside from current share levels, the analyst tells investors in a research note. The firm views Guardant as one of the best growth stories in healthcare. It sees upside to near-term estimates. The company’s “market-leading” liquid therapy selection product offering is getting better and the addressable market is getting bigger, says Wolfe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $70 from $60 at JPMorgan
- Guardant Health upgraded to Outperform from Peer Perform at Wolfe Research
- Guardant Health price target raised to $80 from $70 at UBS
- Guardant Health’s Strategic Advancements and Growth Potential Earns Buy Rating
- Guardant Health Hosts Investor Day in NYC